{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:24:26Z","timestamp":1785795866313,"version":"3.56.0"},"reference-count":201,"publisher":"Oxford University Press (OUP)","issue":"suppl 6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuro Oncol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1093\/neuonc\/nov169","type":"journal-article","created":{"date-parts":[[2015,9,24]],"date-time":"2015-09-24T16:12:51Z","timestamp":1443111171000},"page":"vi1-vi26","source":"Crossref","is-referenced-by-count":41,"title":["CNS Anticancer Drug Discovery and Development Conference White Paper"],"prefix":"10.1093","volume":"17","author":[{"given":"Victor A.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Tonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Birtwistle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvin C.","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Iavarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Paddison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Heffron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Elmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean E.","family":"Lachowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest M.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohee","family":"Sul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Samala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell C.","family":"Petter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,9,24]]},"reference":[{"key":"2015092409124253000_17.suppl_6.vi1.1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not151"},{"key":"2015092409124253000_17.suppl_6.vi1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00105-1"},{"key":"2015092409124253000_17.suppl_6.vi1.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1052-5149(03)00016-9"},{"key":"2015092409124253000_17.suppl_6.vi1.4","unstructured":"Mehta M Vogelbaum MA Chang S Neoplasms of the central nervous system. In: DeVita VTJ Lawrence TS Rosenberg SA , eds. Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:1700\u20131749."},{"key":"2015092409124253000_17.suppl_6.vi1.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1993.tb00752.x"},{"key":"2015092409124253000_17.suppl_6.vi1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00566-X"},{"key":"2015092409124253000_17.suppl_6.vi1.7","unstructured":"Levin VA Hess KR Choucair A Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003;9 (3):981\u2013990."},{"key":"2015092409124253000_17.suppl_6.vi1.8","unstructured":"Levin VA Hess KR Choucair AK Final report for evaluable patients treated on DM92\u2013035, phase III randomized study of post-irradiation PCV versus DFMO-PCV, for anaplastic gliomas (AG). Neuro Oncol. 2012;14 (Supplement 6):vi74."},{"key":"2015092409124253000_17.suppl_6.vi1.9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910640311"},{"key":"2015092409124253000_17.suppl_6.vi1.10","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199501000-00011"},{"key":"2015092409124253000_17.suppl_6.vi1.11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202759"},{"key":"2015092409124253000_17.suppl_6.vi1.12","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200110000-00018"},{"key":"2015092409124253000_17.suppl_6.vi1.13","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-013-0050-7"},{"key":"2015092409124253000_17.suppl_6.vi1.14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not299"},{"key":"2015092409124253000_17.suppl_6.vi1.15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.16.1246"},{"key":"2015092409124253000_17.suppl_6.vi1.16","unstructured":"Jin W Xu X Yang T Hua Z . p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas. Chin Med J (Engl). 2000;113 (7):662\u2013666."},{"key":"2015092409124253000_17.suppl_6.vi1.17","doi-asserted-by":"publisher","DOI":"10.5414\/NPP26224"},{"key":"2015092409124253000_17.suppl_6.vi1.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61702-6"},{"key":"2015092409124253000_17.suppl_6.vi1.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011093431901"},{"key":"2015092409124253000_17.suppl_6.vi1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043331"},{"key":"2015092409124253000_17.suppl_6.vi1.21","doi-asserted-by":"publisher","DOI":"10.3109\/00016925309136718"},{"key":"2015092409124253000_17.suppl_6.vi1.22","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1994.81.5.0690"},{"key":"2015092409124253000_17.suppl_6.vi1.23","doi-asserted-by":"crossref","unstructured":"Packer RJ Goldwein J Nicholson HS Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J Clin Oncol. 1999;17 (7):2127\u20132136.","DOI":"10.1200\/JCO.1999.17.7.2127"},{"key":"2015092409124253000_17.suppl_6.vi1.24","doi-asserted-by":"crossref","unstructured":"Zeltzer PM Boyett JM Finlay JL Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17 (3):832.","DOI":"10.1200\/JCO.1999.17.3.832"},{"key":"2015092409124253000_17.suppl_6.vi1.25","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0922-z"},{"key":"2015092409124253000_17.suppl_6.vi1.26","doi-asserted-by":"publisher","DOI":"10.1021\/jm00305a010"},{"key":"2015092409124253000_17.suppl_6.vi1.27","doi-asserted-by":"publisher","DOI":"10.1021\/jm00243a001"},{"key":"2015092409124253000_17.suppl_6.vi1.28","unstructured":"Levin VA Crafts D Wilson CB Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors. Cancer Chemother Rep. 1975;59 (2 Pt 1):327\u2013331."},{"key":"2015092409124253000_17.suppl_6.vi1.29","doi-asserted-by":"publisher","DOI":"10.1021\/jm00212a024"},{"key":"2015092409124253000_17.suppl_6.vi1.30","unstructured":"Fink SI Leo A Yamakawa M The quantitative structure-selectivity relationship of anthracycline antitumor activity and cardiac toxicity. Farmaco [Sci]. 1980;35 (12):965\u2013979."},{"key":"2015092409124253000_17.suppl_6.vi1.31","doi-asserted-by":"publisher","DOI":"10.1021\/jm00184a007"},{"key":"2015092409124253000_17.suppl_6.vi1.32","doi-asserted-by":"publisher","DOI":"10.1021\/jm00345a015"},{"key":"2015092409124253000_17.suppl_6.vi1.33","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600760902"},{"key":"2015092409124253000_17.suppl_6.vi1.34","unstructured":"Lober G Geller K Hanschmann H Cationic anticancer drugs and their modes of action. Physiologie. 1989;26 (4):305\u2013316."},{"key":"2015092409124253000_17.suppl_6.vi1.35","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(95)03356-P"},{"key":"2015092409124253000_17.suppl_6.vi1.36","doi-asserted-by":"publisher","DOI":"10.1021\/cr010154c"},{"key":"2015092409124253000_17.suppl_6.vi1.37","doi-asserted-by":"publisher","DOI":"10.1021\/cr0102009"},{"key":"2015092409124253000_17.suppl_6.vi1.38","doi-asserted-by":"publisher","DOI":"10.1021\/ci020378b"},{"key":"2015092409124253000_17.suppl_6.vi1.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2003.11.037"},{"key":"2015092409124253000_17.suppl_6.vi1.40","doi-asserted-by":"publisher","DOI":"10.1021\/jm00251a001"},{"key":"2015092409124253000_17.suppl_6.vi1.41","unstructured":"Levin VA Kabra P . Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. Cancer Chemother Rep. 1974;58 (6):787\u2013792."},{"key":"2015092409124253000_17.suppl_6.vi1.42","doi-asserted-by":"publisher","DOI":"10.1021\/cn100008c"},{"key":"2015092409124253000_17.suppl_6.vi1.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0720"},{"key":"2015092409124253000_17.suppl_6.vi1.44","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399411001888"},{"key":"2015092409124253000_17.suppl_6.vi1.45","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32833229e3"},{"key":"2015092409124253000_17.suppl_6.vi1.46","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.1.3"},{"key":"2015092409124253000_17.suppl_6.vi1.47","doi-asserted-by":"crossref","unstructured":"Pardridge WM . CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998;70 (5):1781\u20131792.","DOI":"10.1046\/j.1471-4159.1998.70051781.x"},{"key":"2015092409124253000_17.suppl_6.vi1.48","doi-asserted-by":"publisher","DOI":"10.1021\/jm990017w"},{"key":"2015092409124253000_17.suppl_6.vi1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2010.03.010"},{"key":"2015092409124253000_17.suppl_6.vi1.50","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039255"},{"key":"2015092409124253000_17.suppl_6.vi1.51","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10424"},{"key":"2015092409124253000_17.suppl_6.vi1.52","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.044719"},{"key":"2015092409124253000_17.suppl_6.vi1.53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07208.x"},{"key":"2015092409124253000_17.suppl_6.vi1.54","doi-asserted-by":"publisher","DOI":"10.2174\/138161211797440186"},{"key":"2015092409124253000_17.suppl_6.vi1.55","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0552"},{"key":"2015092409124253000_17.suppl_6.vi1.56","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not002"},{"key":"2015092409124253000_17.suppl_6.vi1.57","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.71"},{"key":"2015092409124253000_17.suppl_6.vi1.58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900034"},{"key":"2015092409124253000_17.suppl_6.vi1.59","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1975.00490540029003"},{"key":"2015092409124253000_17.suppl_6.vi1.60","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.4A6358.2004"},{"key":"2015092409124253000_17.suppl_6.vi1.61","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.1.88"},{"key":"2015092409124253000_17.suppl_6.vi1.62","doi-asserted-by":"crossref","unstructured":"Ernestus RI Rohn G Schroder R Polyamine metabolism in gliomas. J Neurooncol. 1996;29 (2):167\u2013174.","DOI":"10.1007\/BF00182140"},{"key":"2015092409124253000_17.suppl_6.vi1.63","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22914"},{"key":"2015092409124253000_17.suppl_6.vi1.64","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23283"},{"key":"2015092409124253000_17.suppl_6.vi1.65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0690"},{"key":"2015092409124253000_17.suppl_6.vi1.66","doi-asserted-by":"crossref","unstructured":"Regina A Demeule M Tripathy S ANG4043, a novel brain-penetrant peptide-mab conjugate, is efficacious against HER2-positive intracranial tumors in mice. Mol Cancer Ther. 2014;14 1:129\u2013140.","DOI":"10.1158\/1535-7163.MCT-14-0399"},{"key":"2015092409124253000_17.suppl_6.vi1.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.06.176"},{"key":"2015092409124253000_17.suppl_6.vi1.68","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2082"},{"key":"2015092409124253000_17.suppl_6.vi1.69","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1796"},{"key":"2015092409124253000_17.suppl_6.vi1.70","doi-asserted-by":"publisher","DOI":"10.1021\/cb800306y"},{"key":"2015092409124253000_17.suppl_6.vi1.71","doi-asserted-by":"crossref","unstructured":"Singh J Petter RC Baillie TA Whitty A . The resurgence of covalent drugs. Nature Reviews. 2011;10 (4):307\u2013317.","DOI":"10.1038\/nrd3410"},{"key":"2015092409124253000_17.suppl_6.vi1.72","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0287"},{"key":"2015092409124253000_17.suppl_6.vi1.73","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.181545"},{"key":"2015092409124253000_17.suppl_6.vi1.74","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203489"},{"key":"2015092409124253000_17.suppl_6.vi1.75","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01644-12"},{"key":"2015092409124253000_17.suppl_6.vi1.76","doi-asserted-by":"publisher","DOI":"10.1038\/nature08712"},{"key":"2015092409124253000_17.suppl_6.vi1.77","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2734"},{"key":"2015092409124253000_17.suppl_6.vi1.78","doi-asserted-by":"publisher","DOI":"10.1126\/science.1220834"},{"key":"2015092409124253000_17.suppl_6.vi1.79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2199"},{"key":"2015092409124253000_17.suppl_6.vi1.80","doi-asserted-by":"publisher","DOI":"10.1038\/nature11127"},{"key":"2015092409124253000_17.suppl_6.vi1.81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"2015092409124253000_17.suppl_6.vi1.82","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.006908"},{"key":"2015092409124253000_17.suppl_6.vi1.83","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/30.1.149"},{"key":"2015092409124253000_17.suppl_6.vi1.84","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5461.2185"},{"key":"2015092409124253000_17.suppl_6.vi1.85","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.003293"},{"key":"2015092409124253000_17.suppl_6.vi1.86","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.22771"},{"key":"2015092409124253000_17.suppl_6.vi1.87","doi-asserted-by":"publisher","DOI":"10.1002\/glia.21148"},{"key":"2015092409124253000_17.suppl_6.vi1.88","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0353"},{"key":"2015092409124253000_17.suppl_6.vi1.89","doi-asserted-by":"publisher","DOI":"10.1101\/gad.212548.112"},{"key":"2015092409124253000_17.suppl_6.vi1.90","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2013.12.014"},{"key":"2015092409124253000_17.suppl_6.vi1.91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0645"},{"key":"2015092409124253000_17.suppl_6.vi1.92","doi-asserted-by":"publisher","DOI":"10.3390\/toxins5122488"},{"key":"2015092409124253000_17.suppl_6.vi1.93","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.281055"},{"key":"2015092409124253000_17.suppl_6.vi1.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.phytochem.2006.11.032"},{"key":"2015092409124253000_17.suppl_6.vi1.95","doi-asserted-by":"publisher","DOI":"10.1016\/0300-9084(90)90067-Q"},{"key":"2015092409124253000_17.suppl_6.vi1.96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311333110"},{"key":"2015092409124253000_17.suppl_6.vi1.97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060498"},{"key":"2015092409124253000_17.suppl_6.vi1.98","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-396962-0.00009-4"},{"key":"2015092409124253000_17.suppl_6.vi1.99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016112"},{"key":"2015092409124253000_17.suppl_6.vi1.100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000499"},{"key":"2015092409124253000_17.suppl_6.vi1.101","doi-asserted-by":"publisher","DOI":"10.1002\/prot.22441"},{"key":"2015092409124253000_17.suppl_6.vi1.102","doi-asserted-by":"publisher","DOI":"10.2174\/138161211798999375"},{"key":"2015092409124253000_17.suppl_6.vi1.103","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3948"},{"key":"2015092409124253000_17.suppl_6.vi1.104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043696"},{"key":"2015092409124253000_17.suppl_6.vi1.105","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr706"},{"key":"2015092409124253000_17.suppl_6.vi1.106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009536"},{"key":"2015092409124253000_17.suppl_6.vi1.107","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.65"},{"key":"2015092409124253000_17.suppl_6.vi1.108","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0847"},{"key":"2015092409124253000_17.suppl_6.vi1.109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2015092409124253000_17.suppl_6.vi1.110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2935"},{"key":"2015092409124253000_17.suppl_6.vi1.111","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1977.46.2.0145"},{"key":"2015092409124253000_17.suppl_6.vi1.112","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1977.47.3.0329"},{"key":"2015092409124253000_17.suppl_6.vi1.113","doi-asserted-by":"crossref","unstructured":"Macdonald DR Cascino TL Schold SC Jr. Cairncross JG . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8 (7):1277\u20131280.","DOI":"10.1200\/JCO.1990.8.7.1277"},{"key":"2015092409124253000_17.suppl_6.vi1.114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"2015092409124253000_17.suppl_6.vi1.115","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e318223f5a7"},{"key":"2015092409124253000_17.suppl_6.vi1.116","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq203"},{"key":"2015092409124253000_17.suppl_6.vi1.117","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70057-2"},{"key":"2015092409124253000_17.suppl_6.vi1.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.02.011"},{"key":"2015092409124253000_17.suppl_6.vi1.119","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-062"},{"key":"2015092409124253000_17.suppl_6.vi1.120","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/4.2.109"},{"key":"2015092409124253000_17.suppl_6.vi1.121","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000140495.33615.CA"},{"key":"2015092409124253000_17.suppl_6.vi1.122","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000309"},{"key":"2015092409124253000_17.suppl_6.vi1.123","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9637-y"},{"key":"2015092409124253000_17.suppl_6.vi1.124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.2595"},{"key":"2015092409124253000_17.suppl_6.vi1.125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.2464"},{"key":"2015092409124253000_17.suppl_6.vi1.126","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-9976-3"},{"key":"2015092409124253000_17.suppl_6.vi1.127","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9749-4"},{"key":"2015092409124253000_17.suppl_6.vi1.128","doi-asserted-by":"crossref","unstructured":"Friedman HS Petros WP Friedman AH Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17 (5):1516\u20131525.","DOI":"10.1200\/JCO.1999.17.5.1516"},{"key":"2015092409124253000_17.suppl_6.vi1.129","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.1.118"},{"key":"2015092409124253000_17.suppl_6.vi1.130","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000197792.73656.c2"},{"key":"2015092409124253000_17.suppl_6.vi1.131","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1316"},{"key":"2015092409124253000_17.suppl_6.vi1.132","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008382516636"},{"key":"2015092409124253000_17.suppl_6.vi1.133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.7722"},{"key":"2015092409124253000_17.suppl_6.vi1.134","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603376"},{"key":"2015092409124253000_17.suppl_6.vi1.135","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not040"},{"key":"2015092409124253000_17.suppl_6.vi1.136","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5520"},{"key":"2015092409124253000_17.suppl_6.vi1.137","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9225-y"},{"key":"2015092409124253000_17.suppl_6.vi1.138","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq198"},{"key":"2015092409124253000_17.suppl_6.vi1.139","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.7510"},{"key":"2015092409124253000_17.suppl_6.vi1.140","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-005-9062-4"},{"key":"2015092409124253000_17.suppl_6.vi1.141","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5984"},{"key":"2015092409124253000_17.suppl_6.vi1.142","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq072"},{"key":"2015092409124253000_17.suppl_6.vi1.143","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-9950-0"},{"key":"2015092409124253000_17.suppl_6.vi1.144","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.096"},{"key":"2015092409124253000_17.suppl_6.vi1.145","doi-asserted-by":"crossref","unstructured":"Rich JN Reardon DA Peery T Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22 (1):133\u2013142.","DOI":"10.1200\/JCO.2004.08.110"},{"key":"2015092409124253000_17.suppl_6.vi1.146","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0773"},{"key":"2015092409124253000_17.suppl_6.vi1.147","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.9235"},{"key":"2015092409124253000_17.suppl_6.vi1.148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2185"},{"key":"2015092409124253000_17.suppl_6.vi1.149","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24213"},{"key":"2015092409124253000_17.suppl_6.vi1.150","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1041-6"},{"key":"2015092409124253000_17.suppl_6.vi1.151","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.23.622"},{"key":"2015092409124253000_17.suppl_6.vi1.152","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2323"},{"key":"2015092409124253000_17.suppl_6.vi1.153","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.0694"},{"key":"2015092409124253000_17.suppl_6.vi1.154","unstructured":"Levin VA Leibel SA Gutin PH . Neoplasms of the central nervous system. In: DeVita VTJ Hellman S Rosenberg SA , eds. Cancer: Principles and Practice of Oncology. 6th edn. Philadelphia: Lippincott-Raven; 2001:2100\u20132160."},{"key":"2015092409124253000_17.suppl_6.vi1.155","unstructured":"Schold SC Jr. Friedman HS Bjornsson TD Bigner DD . Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations. Cancer Res. 1984;44 (6):2352\u20132357."},{"key":"2015092409124253000_17.suppl_6.vi1.156","unstructured":"Allen JC Bloom J Ertel I Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. [review]. Semin Oncol. 1986;13 (1):110\u2013122."},{"key":"2015092409124253000_17.suppl_6.vi1.157","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901215)66:12<2465::AID-CNCR2820661204>3.0.CO;2-N"},{"key":"2015092409124253000_17.suppl_6.vi1.158","doi-asserted-by":"crossref","unstructured":"Allen JC Walker R Luks E Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987;5 (3):459\u2013463.","DOI":"10.1200\/JCO.1987.5.3.459"},{"key":"2015092409124253000_17.suppl_6.vi1.159","unstructured":"Rosen G Ghavimi F Nirenberg A High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children. Cancer Treat Rep. 1977;61 (4):681\u2013690."},{"key":"2015092409124253000_17.suppl_6.vi1.160","unstructured":"Djerassi I Kim JS Shulman K . High-dose methotrexate-citrovorum factor rescue in the management of brain tumors. Cancer Treat Rep. 1977;61:691."},{"key":"2015092409124253000_17.suppl_6.vi1.161","doi-asserted-by":"publisher","DOI":"10.1007\/BF00446227"},{"key":"2015092409124253000_17.suppl_6.vi1.162","unstructured":"Walker R JC A . Treatment of recurrent primary intracranial childhood tumors with cis-diamine-dichloroplatinum. Ann Neurol. 1983;14:371."},{"key":"2015092409124253000_17.suppl_6.vi1.163","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7"},{"key":"2015092409124253000_17.suppl_6.vi1.164","doi-asserted-by":"crossref","unstructured":"Friedman HS Schold SC Jr. Mahaley MS Jr. Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. J Clin Oncol. 1989;7 (7):904\u2013911.","DOI":"10.1200\/JCO.1989.7.7.904"},{"key":"2015092409124253000_17.suppl_6.vi1.165","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1984.61.6.1063"},{"key":"2015092409124253000_17.suppl_6.vi1.166","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1976.45.2.0135"},{"key":"2015092409124253000_17.suppl_6.vi1.167","unstructured":"Smart CR Ottoman RE Rochlin DB Clinical experience with vincristine in tumors of the central nervous system and other malignant diseases. Cancer Chemother Rep. 1968;52:733."},{"key":"2015092409124253000_17.suppl_6.vi1.168","unstructured":"Haddy TB Ferbach DJ Watkins WL Vincristine in uncommon malignant disease in children. Cancer Chemother Rep. 1964;41:41."},{"key":"2015092409124253000_17.suppl_6.vi1.169","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1976.00500110007002"},{"key":"2015092409124253000_17.suppl_6.vi1.170","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5908.642"},{"key":"2015092409124253000_17.suppl_6.vi1.171","unstructured":"Fewer D Wilson CB Boldrey EB Phase II study of 1-(2-choloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of brain tumors. Cancer Chemother Rep. 1972;56:421."},{"key":"2015092409124253000_17.suppl_6.vi1.172","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950120103"},{"key":"2015092409124253000_17.suppl_6.vi1.173","doi-asserted-by":"crossref","unstructured":"Edwards MS Levin VA Wilson CB . Chemotherapy of recurrent pediatric posterior fossa tumors. Clin Neurosurg. 1983;30:209\u2013225.","DOI":"10.1093\/neurosurgery\/30.CN_suppl_1.209"},{"key":"2015092409124253000_17.suppl_6.vi1.174","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1978.49.4.0589"},{"key":"2015092409124253000_17.suppl_6.vi1.175","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80662-0"},{"key":"2015092409124253000_17.suppl_6.vi1.176","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230506"},{"key":"2015092409124253000_17.suppl_6.vi1.177","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1978.49.3.0333"},{"key":"2015092409124253000_17.suppl_6.vi1.178","unstructured":"Levin VA Wara WM Davis RL Northern California Oncology Group protocol 6G91: response to treatment with radiation therapy and seven-drug chemotherapy in patients with glioblastoma multiforme. Cancer Treat Rep. 1986;70 (6):739\u2013743."},{"key":"2015092409124253000_17.suppl_6.vi1.179","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(90)90096-3"},{"key":"2015092409124253000_17.suppl_6.vi1.180","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90690-6"},{"key":"2015092409124253000_17.suppl_6.vi1.181","doi-asserted-by":"crossref","unstructured":"Dinapoli RP Brown LD Arusell RM Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol. 1993;11 (7):1316\u20131321.","DOI":"10.1200\/JCO.1993.11.7.1316"},{"key":"2015092409124253000_17.suppl_6.vi1.182","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00160-Z"},{"key":"2015092409124253000_17.suppl_6.vi1.183","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00122-4"},{"key":"2015092409124253000_17.suppl_6.vi1.184","unstructured":"Levin VA Uhm JH Jaeckle KA Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 2000;6 (10):3878\u20133884."},{"key":"2015092409124253000_17.suppl_6.vi1.185","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"2015092409124253000_17.suppl_6.vi1.186","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.04.011"},{"key":"2015092409124253000_17.suppl_6.vi1.187","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1308573"},{"key":"2015092409124253000_17.suppl_6.vi1.188","doi-asserted-by":"crossref","unstructured":"Jeremic B Jovanovic D Djuric LJ Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. J Chemother. 1992;4 (2):123\u2013126.","DOI":"10.1080\/1120009X.1992.11739152"},{"key":"2015092409124253000_17.suppl_6.vi1.189","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)00488-7"},{"key":"2015092409124253000_17.suppl_6.vi1.190","doi-asserted-by":"crossref","unstructured":"Prados MD Scott C Curran WJ Jr Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 1999;17 (11):3389\u20133395.","DOI":"10.1200\/JCO.1999.17.11.3389"},{"key":"2015092409124253000_17.suppl_6.vi1.191","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00265-5"},{"key":"2015092409124253000_17.suppl_6.vi1.192","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)02819-X"},{"key":"2015092409124253000_17.suppl_6.vi1.193","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.08.024"},{"key":"2015092409124253000_17.suppl_6.vi1.194","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.5148"},{"key":"2015092409124253000_17.suppl_6.vi1.195","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4324"},{"key":"2015092409124253000_17.suppl_6.vi1.196","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.66"},{"key":"2015092409124253000_17.suppl_6.vi1.197","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003088"},{"key":"2015092409124253000_17.suppl_6.vi1.198","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0958-8"},{"key":"2015092409124253000_17.suppl_6.vi1.199","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4974"},{"key":"2015092409124253000_17.suppl_6.vi1.200","unstructured":"Levin VA . Pharmacokinetics and central nervous system chemotherapy. In: Hellmann K Carter SK , eds. Fundamentals of Cancer Chemotherapy. New York: McGraw-Hill; 1987:28\u201340."},{"key":"2015092409124253000_17.suppl_6.vi1.201","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2356"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/17\/suppl_6\/vi1\/3800078\/nov169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T23:14:47Z","timestamp":1567206887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nov169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,24]]},"references-count":201,"journal-issue":{"issue":"suppl 6","published-online":{"date-parts":[[2015,9,24]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1093\/neuonc\/nov169"],"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nov169","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,24]]}}}